Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s

Lundbeck Obtains Rights to Research that Targets Immune Checkpoint Pathways in Alzheimer’s
Lundbeck, a global pharmaceutical company specializing in therapies for neurological disorders, has obtained the rights to IBC’s (ImmunoBrain Checkpoint) groundbreaking research into treatment for Alzheimer’s disease. "IBC has a unique and innovative approach to this highly complex disease and the data generated until now are highly promising," Jacob Tolstrup, executive vice president for corporate functions at Lundbeck, said in a press release. "We are delighted to take part in this exciting work as part of our strategy of in-licensing research projects to supplement our own research activities." In particular, IBC’s lead program, which is being developed specifically for Alzheimer’s disease, blocks the PD-1/PD-L1 immune checkpoint pathway. Drugs targeting this pathway already are used in cancer treatment, and their use could be extended to the treatment of neurodegenerative diseases. Immune checkpoint pathways are involved in regulating the immune system balance. Studies have found blocking the PD-1 pathway has anti-tumor activity as it mobilizes the immune system to fight cancer cells by activating the IFN-γ (interferon gamma; a critical cytokine for immune responses) dependent pathway. Interestingly, activation of the IFN-γ pathway also was found to lead to the repair of the central nervous system as it stimulated leukocytes to enter into the brain. A study titled “PD-1 immune checkpoint blockade reduces pathology and improves memory in m
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *